- Home
- EHC vs LEGN Comparison
EHC vs LEGN Comparison
Compare EHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EHC | LEGN |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 5.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EHC | LEGN |
|---|---|---|
| Price | $99.92 | $18.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $143.29 | $63.08 |
| AVG Volume (30 Days) | 800.1K | ★ 1.5M |
| Earning Date | 04-23-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 24.22 | N/A |
| EPS | ★ 5.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.38 | $46.27 |
| Revenue Next Year | $8.12 | $28.77 |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $92.77 | $16.24 |
| 52 Week High | $127.99 | $45.30 |
Technical Indicators
Market Signals| Indicator | EHC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 44.37 |
| Support Level | $98.24 | $17.46 |
| Resistance Level | $109.14 | $20.39 |
| Average True Range (ATR) | 2.91 | 0.73 |
| MACD | -0.95 | 0.03 |
| Stochastic Oscillator | 7.81 | 23.89 |
Price Performance
Historical ComparisonAbout EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.